The DOI matches its Crossref record.
Fibrin d -Dimer and β-Thromboglobulin as Markers of Thrombogenesis and Platelet Activation in Atrial Fibrillation: Effects of Introducing Ultra–Low-Dose Warfarin and Aspirin
Abstract
Background Previous studies have demonstrated increased markers of thrombogenesis in patients with atrial fibrillation (AF), suggesting the presence of a hypercoagulable or prothrombotic state. The objective of this study was to determine the effects of introducing ultra–low-dose warfarin (1 mg), conventional warfarin, and aspirin (300 mg) therapy on thrombogenesis and platelet activation in AF. Methods and Results We measured sequential changes in plasma fibrin d -dimer (an index of thrombogenesis) and β-thromboglobulin (β-TG, a measure of platelet activation) in 51 patients with chronic AF before and at 2 and 6 weeks after randomization to either 1 mg warfarin or 300 mg aspirin (phase 1). Then all patients were started on conventional warfarin therapy (phase 2) with samples taken 2 and 6 weeks later. Pretreatment results were compared with those from 26 healthy control subjects in sinus rhythm. Baseline (pretreatment) β-TG and d -dimer levels in patients with AF were elevated compared with those of control subjects ( P <.001). In phase 1, there were no significant changes in median levels of fibrin d -dimer or β-TG, despite warfarin 1 mg or aspirin 300 mg. With standard warfarin therapy (phase 2), there was a reduction in median β-TG at 6 weeks ( P =.025) and a sequential reduction in median d -dimer levels at 2 ( P =.001) and 6 ( P <.001) weeks compared with baseline levels. Conclusions Patients with AF have increased intravascular thrombogenesis and platelet activation compared with patients in sinus rhythm. Introduction of ultra–low-dose warfarin (1 mg) or aspirin 300 mg does not significantly alter these markers, although conventional warfarin therapy reduces β-TG and fibrin d -dimer levels. This is consistent with the beneficial effect of full-dose warfarin in preventing stroke and thromboembolism in AF and suggests that ultra–low-dose warfarin and aspirin may not exert similar beneficial effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L. E., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,348
Wassertheil-Smoller, S., Hendrix, S., Limacher, M., Heiss, G., Kooperberg, C., Baird, A., Kotchen, T., Curb, J. D., Black, H., Rossouw, J. E., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2673 · Cited by 1,159
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,123
Self-citationFuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J.-Y., Lowe, J. E., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.013 · Cited by 924
Metadata
- Authors
- Lip, G. Y. H., Lip, P. L., Zarifis, J., Watson, R. D. S., Bareford, D., Lowe, G. D. O., & Beevers, D. G.
- Venue
- Circulation
- Published
- 1996-08
- Volume
- 94
- Issue
- 3
- Pages
- 425-431
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2078573963
- Cited by
- 246
- References
- 0
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrin d -Dimer and β-Thromboglobulin as Markers of Thrombogenesis and Platelet Activation in Atrial Fibrillation: Effects of Introducing Ultra–Low-Dose Warfarin and Aspirin. https://app.cochat.ai/papers/10.1161/01.cir.94.3.425
- The paper
- Lip, G. Y. H., Lip, P. L., Zarifis, J., Watson, R. D. S., Bareford, D., Lowe, G. D. O., & Beevers, D. G. (1996). Fibrin d -Dimer and β-Thromboglobulin as Markers of Thrombogenesis and Platelet Activation in Atrial Fibrillation: Effects of Introducing Ultra–Low-Dose Warfarin and Aspirin. Circulation. https://doi.org/10.1161/01.cir.94.3.425
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.